Whilst it may not be a huge deal, we thought it was good to see that the CelLBxHealth plc (LON:CLBX) Secretary & Executive Chairman, Jan Groen, recently bought UK£50k worth of stock, for UK£0.01 per share. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

In fact, the recent purchase by Jan Groen was the biggest purchase of CelLBxHealth shares made by an insider individual in the last twelve months, according to our records. That implies that an insider found the current price of UK£0.011 per share to be enticing. That means they have been optimistic about the company in the past, though they may have changed their mind. If someone buys shares at well below current prices, it’s a good sign on balance, but keep in mind they may no longer see value. In this case we’re pleased to report that the insider purchases were made at close to current prices.

In the last twelve months CelLBxHealth insiders were buying shares, but not selling. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

See our latest analysis for CelLBxHealth

insider-trading-volume

AIM:CLBX Insider Trading Volume December 22nd 2025

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it’s a good sign if insiders own a significant number of shares in the company. Insiders own 14% of CelLBxHealth shares, worth about UK£473k, according to our data. Overall, this level of ownership isn’t that impressive, but it’s certainly better than nothing!

The recent insider purchases are heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that CelLBxHealth insiders are expecting a bright future. In addition to knowing about insider transactions going on, it’s beneficial to identify the risks facing CelLBxHealth. Case in point: We’ve spotted 4 warning signs for CelLBxHealth you should be aware of, and 2 of them are a bit concerning.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.